1. Home
  2. PHAT vs TSSI Comparison

PHAT vs TSSI Comparison

Compare PHAT & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • TSSI
  • Stock Information
  • Founded
  • PHAT 2018
  • TSSI 2004
  • Country
  • PHAT United States
  • TSSI United States
  • Employees
  • PHAT N/A
  • TSSI N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • TSSI Professional Services
  • Sector
  • PHAT Health Care
  • TSSI Consumer Discretionary
  • Exchange
  • PHAT Nasdaq
  • TSSI Nasdaq
  • Market Cap
  • PHAT 716.5M
  • TSSI 677.8M
  • IPO Year
  • PHAT 2019
  • TSSI N/A
  • Fundamental
  • Price
  • PHAT $11.91
  • TSSI $15.40
  • Analyst Decision
  • PHAT Strong Buy
  • TSSI
  • Analyst Count
  • PHAT 5
  • TSSI 0
  • Target Price
  • PHAT $16.40
  • TSSI N/A
  • AVG Volume (30 Days)
  • PHAT 1.1M
  • TSSI 3.5M
  • Earning Date
  • PHAT 08-07-2025
  • TSSI 08-06-2025
  • Dividend Yield
  • PHAT N/A
  • TSSI N/A
  • EPS Growth
  • PHAT N/A
  • TSSI 311.74
  • EPS
  • PHAT N/A
  • TSSI 0.34
  • Revenue
  • PHAT $114,039,000.00
  • TSSI $263,021,000.00
  • Revenue This Year
  • PHAT $194.40
  • TSSI N/A
  • Revenue Next Year
  • PHAT $103.23
  • TSSI N/A
  • P/E Ratio
  • PHAT N/A
  • TSSI $43.93
  • Revenue Growth
  • PHAT 1049.82
  • TSSI 328.79
  • 52 Week Low
  • PHAT $2.21
  • TSSI $4.13
  • 52 Week High
  • PHAT $19.71
  • TSSI $31.94
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 75.25
  • TSSI 33.85
  • Support Level
  • PHAT $9.82
  • TSSI $13.88
  • Resistance Level
  • PHAT $11.19
  • TSSI $15.63
  • Average True Range (ATR)
  • PHAT 0.71
  • TSSI 1.96
  • MACD
  • PHAT 0.17
  • TSSI -0.80
  • Stochastic Oscillator
  • PHAT 94.07
  • TSSI 8.52

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About TSSI TSS Inc. Common Stock

TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.

Share on Social Networks: